Adam Cseresznye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Adam Cseresznye has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Covaci
University of Antwerp
8 shared publications - Fatima Den Ouden
Toxicological Centre, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium; Centre for Environmental Sciences, Hasselt University, Agoralaan, 3590 Diepenbeek, Belgium
5 shared publications - Giulia Poma
Toxicological Centre, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
5 shared publications - Roger Pero-Gascon
Center of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University
5 shared publications - Elias Maris
Centre of Excellence in Mycotoxicology and Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Leuven, Belgium
4 shared publications - Ellen De Paepe
Laboratory of Integrative Metabolomics (LIMET), Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
4 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
A validated dual-extraction approach for comprehensive ultra-high performance liquid chromatography-high resolution mass spectrometry-based metabolomics and lipidomics of human placenta applied to the ENVIRONAGE birth cohort
The placenta is the interface between maternal exposome and fetal development. However, analytical platforms for simultaneous analysis of its (semi-)polar metabolome and lipidome from a single tissue aliquot are lacking. We developed and validated a dual-extraction method for metabolomics and lipidomics analyses of human placenta.,A Design of Experiments approach was based on 54 targeted metabolites and lipids (log P=–3.24-10.59) and untargeted feature count to optimize bead mill homogenization, solvent composition and dilution for sequential extraction, prior to ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry. Method validation was performed on pooled porcine (as a proxy) and human placenta samples. Targeted validation demonstrated a coefficient of variation (CV) ≤20% for repeatability and inter-day precision and a coefficient of determination (R²) ≥0.99 for >26/27 metabolites and >17/27 lipids. Untargeted analysis consistently detected 2,811 and 5,412 features (CV ≤30%) in metabolite and lipid fractions, respectively.,The method was applied to 371 placental samples from the ENVIRONAGE birth cohort to assess metabolic perturbations associated with maternal lifestyle factors and adverse neonatal outcomes (small for gestational age (SGA) status, preterm birth, and low 1-minute Appearance, Pulse, Grimace, Activity and Respiration (APGAR)). Notably, placental cotinine levels showed associations with self-reported maternal smoking behavior (η² =0.14, FDR p <0.2). Pathway enrichment and targeted analyses identified outcome-specific metabolic signatures under basic covariate adjustment, though these were sensitive to extended covariate correction.,Our validated dual-extraction platform enables reproducible, resource-efficient placental phenotyping with demonstrated sensitivity to exposome signals, supporting large-scale birth cohort research into adverse neonatal outcomes.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA validated dual-extraction approach for comprehensive ultra-high performance liquid chromatography-high resolution mass spectrometry-based metabolomics and lipidomics of human placenta applied to the ENVIRONAGE birth cohort
The placenta is the interface between maternal exposome and fetal development. However, analytical platforms for simultaneous analysis of its (semi-)polar metabolome and lipidome from a single tissue aliquot are lacking. We developed and validated a dual-extraction method for metabolomics and lipidomics analyses of human placenta.,A Design of Experiments approach was based on 54 targeted metabolites and lipids (log P=–3.24-10.59) and untargeted feature count to optimize bead mill homogenization, solvent composition and dilution for sequential extraction, prior to ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry. Method validation was performed on pooled porcine (as a proxy) and human placenta samples. Targeted validation demonstrated a coefficient of variation (CV) ≤20% for repeatability and inter-day precision and a coefficient of determination (R²) ≥0.99 for >26/27 metabolites and >17/27 lipids. Untargeted analysis consistently detected 2,811 and 5,412 features (CV ≤30%) in metabolite and lipid fractions, respectively.,The method was applied to 371 placental samples from the ENVIRONAGE birth cohort to assess metabolic perturbations associated with maternal lifestyle factors and adverse neonatal outcomes (small for gestational age (SGA) status, preterm birth, and low 1-minute Appearance, Pulse, Grimace, Activity and Respiration (APGAR)). Notably, placental cotinine levels showed associations with self-reported maternal smoking behavior (η² =0.14, FDR p <0.2). Pathway enrichment and targeted analyses identified outcome-specific metabolic signatures under basic covariate adjustment, though these were sensitive to extended covariate correction.,Our validated dual-extraction platform enables reproducible, resource-efficient placental phenotyping with demonstrated sensitivity to exposome signals, supporting large-scale birth cohort research into adverse neonatal outcomes.
- 19 February 2026
- Published by Elsevier in Environmental Research
- Vol. 296, 124068
Serum PCBs, OCPs, PBDEs and PCAs: Associations with metabolic syndrome risk factors in the Flemish Gut Flora Project cohort
- 19 February 2026
- Published by Elsevier in Environmental Research
- Vol. 296, 124068
Serum PCBs, OCPs, PBDEs and PCAs: Associations with metabolic syndrome risk factors in the Flemish Gut Flora Project cohort
- 16 December 2025
- Published by Elsevier in Environmental Research
- Vol. 291, 123572
Prenatal exposure to persistent organic pollutants and sex-specific neonatal outcomes in the ENVIRONAGE birth cohort
- 16 December 2025
- Published by Elsevier in Environmental Research
- Vol. 291, 123572
Prenatal exposure to persistent organic pollutants and sex-specific neonatal outcomes in the ENVIRONAGE birth cohort
- 4 November 2025
- Published by Elsevier in Environmental Research
- Vol. 288 (Pt 1) , 123275
Chemical exposure in childhood: A study on organophosphate flame retardants and plasticizers in a Flemish birth cohort
- 4 November 2025
- Published by Elsevier in Environmental Research
- Vol. 288 (Pt 1) , 123275
Chemical exposure in childhood: A study on organophosphate flame retardants and plasticizers in a Flemish birth cohort
- 6 August 2025
- Published by Elsevier in Food Control
- Vol. 180
Short-, medium- and long-chain chlorinated paraffins in novel plant-based foods – Occurrence, patterns and food safety assessment
- 6 August 2025
- Published by Elsevier in Food Control
- Vol. 180
Short-, medium- and long-chain chlorinated paraffins in novel plant-based foods – Occurrence, patterns and food safety assessment
- 15 April 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 493, 138305
Cumulative exposure assessment to polychlorinated alkanes (C8–36) to indoor dust from Iranian kindergartens: Occurrence and health risk
- 15 April 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 493, 138305
Cumulative exposure assessment to polychlorinated alkanes (C8–36) to indoor dust from Iranian kindergartens: Occurrence and health risk
- 24 February 2024
- Published by Elsevier in Environmental Research
- Vol. 250, 118537
HBM4EU E-waste study: Assessing persistent organic pollutants in blood, silicone wristbands, and settled dust among E-waste recycling workers in Europe
- 24 February 2024
- Published by Elsevier in Environmental Research
- Vol. 250, 118537
HBM4EU E-waste study: Assessing persistent organic pollutants in blood, silicone wristbands, and settled dust among E-waste recycling workers in Europe
- Open Access
- 25 September 2023
- Published by SAGE Publications in Neurotrauma Reports
- Vol. 4 (1) , 643-654
Levels of Arachidonic Acid–Derived Oxylipins and Anandamide Are Elevated Among Military APOE ɛ4 Carriers With a History of Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder Symptoms
Currently approved blood biomarkers detect intracranial lesions in adult patients with mild to moderate traumatic brain injury (TBI) acutely post-injury. However, blood biomarkers are still needed to help with a differential diagnosis of mild TBI (mTBI) and post-traumatic stress disorder (PTSD) at chronic post-injury time points. Owing to the association between phospholipid (PL) dysfunction and chronic consequences of TBI, we hypothesized that examining bioactive PL metabolites (oxylipins and ethanolamides) would help identify long-term lipid changes associated with mTBI and PTSD. Lipid extracts of plasma from active-duty soldiers deployed to the Iraq/Afghanistan wars (control = 52, mTBI = 21, PTSD = 34, and TBI + PTSD = 13) were subjected to liquid chromatography/mass spectrometry analysis to examine oxylipins and ethanolamides. Linear regression analyses followed by post hoc comparisons were performed to assess the association of these lipids with diagnostic classifications. Significant differences were found in oxylipins derived from arachidonic acid (AA) between controls and mTBI, PTSD, and mTBI + PTSD groups. Levels of AA-derived oxylipins through the cytochrome P450 pathways and anandamide were significantly elevated among mTBI + PTSD patients who were carriers of the apolipoprotein E E4 allele. These studies demonstrate that AA-derived oxylipins and anandamide may be unique blood biomarkers of PTSD and mTBI + PTSD. Further, these AA metabolites may be indicative of an underlying inflammatory process that warrants further investigation. Future validation studies in larger cohorts are required to determine a potential application of this approach in providing a differential diagnosis of mTBI and PTSD in a clinical setting.
- 25 September 2023
- Published by SAGE Publications in Neurotrauma Reports
- Vol. 4 (1) , 643-654
Open AccessLevels of Arachidonic Acid–Derived Oxylipins and Anandamide Are Elevated Among Military APOE ɛ4 Carriers With a History of Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder Symptoms
Currently approved blood biomarkers detect intracranial lesions in adult patients with mild to moderate traumatic brain injury (TBI) acutely post-injury. However, blood biomarkers are still needed to help with a differential diagnosis of mild TBI (mTBI) and post-traumatic stress disorder (PTSD) at chronic post-injury time points. Owing to the association between phospholipid (PL) dysfunction and chronic consequences of TBI, we hypothesized that examining bioactive PL metabolites (oxylipins and ethanolamides) would help identify long-term lipid changes associated with mTBI and PTSD. Lipid extracts of plasma from active-duty soldiers deployed to the Iraq/Afghanistan wars (control = 52, mTBI = 21, PTSD = 34, and TBI + PTSD = 13) were subjected to liquid chromatography/mass spectrometry analysis to examine oxylipins and ethanolamides. Linear regression analyses followed by post hoc comparisons were performed to assess the association of these lipids with diagnostic classifications. Significant differences were found in oxylipins derived from arachidonic acid (AA) between controls and mTBI, PTSD, and mTBI + PTSD groups. Levels of AA-derived oxylipins through the cytochrome P450 pathways and anandamide were significantly elevated among mTBI + PTSD patients who were carriers of the apolipoprotein E E4 allele. These studies demonstrate that AA-derived oxylipins and anandamide may be unique blood biomarkers of PTSD and mTBI + PTSD. Further, these AA metabolites may be indicative of an underlying inflammatory process that warrants further investigation. Future validation studies in larger cohorts are required to determine a potential application of this approach in providing a differential diagnosis of mTBI and PTSD in a clinical setting.